TNF-α inhibitors: Are they carcinogenic?

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 241-247

  Raval, Girindra ^a   Mehta, Paulette ^b,c  

^a Jefferson Regional Medical Center   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Inflammatory bowel disease; Malignancy; Rheumatoid arthritis; Tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; AMFEBUTAMONE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ANKYLOSING SPONDYLITIS; B CELL LYMPHOMA; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BILE DUCT CARCINOMA; BIOLOGICAL THERAPY; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARCINOID; CAUSAL ATTRIBUTION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON ADENOCARCINOMA; COLON POLYP; CROHN DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ENTERITIS; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIPOSARCOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; LYMPHOMATOID PAPULOSIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYELODYSPLASTIC SYNDROME; OSTEOARTHRITIS; PANCREAS CARCINOMA; PSORIASIS; PSORIATIC ARTHRITIS; RECTUM CARCINOMA; REVIEW; RHEUMATOID ARTHRITIS; SIGNET RING CARCINOMA; SKIN CANCER; SMOKING; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; ULCERATIVE COLITIS; UTERINE CERVIX DYSPLASIA; WEGENER GRANULOMATOSIS;

EID: 78650705801     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S7829     Document Type: Review

References (53)

1. Boyman O, Hefti HP, Conrad C, Nickoloff B, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factord. J Exp Med. 2004;199:731-736.
2. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85:473-483.
3. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2000;121:1-14.
4. Younes A, Aggarwall BB. Clinical Implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer. 2003;98:458-467.
5. Johrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)- alpha via TNF receptor 2 and autocrine upregulation of MCP-1. Clin Cancer Res. 2004;10:1901-1910.
6. Bergeron S, Beauchemin M, Bertrand R. Camptothecin and etoposide induced apoptosis in human leukemia cells is independent of cell death receptor 4 and 4 aggregation but accelerates tumor necrosis factor related apoptosis inducing ligand mediated cell death. Mol Cancer Ther. 2004;3:1659-1669.
7. Lee NS, Cheong HJ, Kim SJ, et al. Ex vivo purging of leukemia cells using tumor necrosis factor related apoptosis inducing ligand in hematopoietic stem cell transplantation. Leukemia. 2003;17:1375-1383.
8. Beyne-Rauzy O, Recher C, Dastugue N, et al. Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. Oncogene. 2004;23:7507-7516.
9. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. TrendsCell Biol. 2001;11:372-377.
10. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
11. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988;47:988-992.
12. Radis CD, Kahl LE, Baker GL, et al. Effect of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20 year followup study. Arthritis Rheum. 1995;38:1120-1127.
13. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotraxate: a 3 year prospective study in France. Blood. 2002;99:3909-3915.
14. Lipsky PE, van der Heijde DM, St Clair EW, et al; for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotraxate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
15. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol. 2004;51:200-204.
16. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFrrlevels during treatment. Leuk Res. 2003;27:375-380.
17. Kane S, Altschuler E, Kast RE. Crohn's disease remission on bupropion. Gastroenterology. 2001;121:1260-1261.
18. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: a nested case - control study. BMJ. 1998;317:180-181.
19. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497-502.
20. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population based study. Cancer. 2001;91:854-862.
21. Brown SL, Greene MH, Greshon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development. Twenty six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
22. Outlaw W, Fleischer A, Bloomfeld R. Lymphomatoid papulosis in a patient with Crohn's disease treated with infliximab. Inflamm Bowel Dis. 2009;15:965-966.
23. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotraxate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:6:1740-1751.
24. Baecklund E, Sundstrom C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 2003;48:1543-1550.
25. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703.
26. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposureadjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-1145.
27. Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of literature. Am J Hematol. 2007;82:1022-1024.
28. Bakland G, Nossent H. Acute myelogenous leukemia following etanercept therapy. Rheumatology. 2003;42:900-901.
29. Saba NS, Kosseifi SG, Charaf EA, et al. Adalimumab-induced acute myelogenous leukemia. South Med J. 2008;101:1261-1262.
30. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;351-361.
31. De Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9 year cohort study in the Netherlands. Drug Saf. 2008;31:1135-1144.
32. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum. 2004;50:11:3432-3443.
33. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimiumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotraxate therapy: a randomized placebo controlled 52 week trial. Arthritis Rheum. 2004;50:1400-1411.
34. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-516.
35. Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
36. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analyses from a large US observational study. Arthritis Rheum. 2007;56:2886-2895.
37. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut. 2006;55:228-233.
38. Lichtenstein GR, Cohen RD, Feagen BG, et al. Safety of infliximab and other Crohn's disease therapies - TREAT registry data with nearly 15,000 patient-years of follow-up. Gastroenterology. 2006;130:A71.
39. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient years follow up. Aliment Pharmacol Ther. 2009;29:286-297.
40. Colombel JF, Loftus EV Jr. The safety profile on infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
41. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926-934.
42. Lees CW, Ironside J, Wallace WA, Satsangi J. Resolution of non small cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med. 2008;539:320-321.
43. Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther. 2009;29:605-614.
44. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
45. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1096-1104.
46. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Internal Med. 2010;25:1-17.
47. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953-956.
48. Essar AC, Arbil A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004;50 Suppl 5:S75-S77.
49. Burge D. Etanercept and squamous cell carcinoma. J Am Acad Dermatol. 2003;49:358-359.
50. Lebwohl M, Blum R, Berkowitz E, et al. No evidence of increased risk of squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005;141:861-864.
51. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135.
52. Ledingham J, Deighton C. Update of the British Society of Rheumatology: guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology. 2005;44:157-163.
53. Saag KG, Teng GG, Patkar NM, et al; for the American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.